PRODUCTS
| API’s | Category | Specifications | Regulatory Status |
|---|---|---|---|
| Atenolol | Anti-Hypertensive | IP/BP/EP/USP | CEP, EU GMP,USDMF, CADIFA Filed |
| Amlodipine Besylate | Anti-Hypertensive | IP/BP/EP/USP | DMF Available, CADIFA Filed, CEP is available |
| Metoprolol Succinate | Anti-Hypertensive | IP/BP/EP/USP | USDMF filed |
| Metoprolol Tartrate | Anti-Hypertensive | IP/BP/EP/USP | USDMF filed |
| Roxithromycin | Macrolides | IP/BP/EP | CEP |
| Azithromycin | Macrolides | IP/BP/EP/USP | CEP, USDMF filed, CADIFA Filed |
| Clarithromycin Granules 27.5% | Macrolides | In-House | DMF Available |
| Clarithromycin Granules 33% | Macrolides | In-House | DMF Available |
| Clarithromycin Granules 43% | Macrolides | In-House | DMF Available |
| Pregabalin | Neuromodulator | IP/EP/USP | CEP, USDMF filed, CADIFA Filed |
| Ceftriaxone Sodium | Sterile Cephalosporins | IP/BP/EP/USP | DMF Available |
| Cefotaxime Sodium | Sterile Cephalosporins | IP/BP/EP/USP | DMF Available |
| Cefepime (with L-Arginine) for Injection | Sterile Cephalosporins | IP/USP | |
| Meropenem (with Sodium Carbonate) for Injection | Carbapenems | IP/USP | DMF Available |
| Doripenem | Carbapenems | JP/In-House | DMF Available |
| Biapenem | Carbapenems | In-House | DMF Available |
| Ertapenem | Carbapenems | In-House | DMF Under Compilation |
| Faropenem | Carbapenems | JP/In-House | DMF Available |
| Lymecycline | Anti-Acne, Anti-Infective |
EP | DMF Available, CEP is available |
| Nitroxoline | Antibiotic (Urological) | In-House | DMF Available |
| Ticagrelor | Anti-Thrombotic | IP/EP/In-House | DMF Available |
| Rivaroxaban | Anti-Thrombotic | EP/USP/In-House | DMF Under Compilation,CEP is available |
| Apixaban | Anti-Thrombotic | In-House | DMF Under Compilation |
| Edoxaban Tosylate | Anti-Thrombotic | In-House | DMF Under Compilation |
| Empagliflozin | Anti-Diabetic | In-House | DMF Available |
| Dapagliflozin Propanediol Monohydrate | Anti-Diabetic | In-House | DMF Under Compilation |
| Montelukast Sodium | Anti-Asthamatic | IP/EP/USP | DMF Under Compilation |
| Rosuvastatin Calcium | Lipid-Lowering agent | IP/EP/USP | DMF Under Compilation |
| Tebipenem | Carbapenems | In-House | DMF Available |
PELLETS
| Pellets | Category |
|---|---|
| Duloxetine Pellets 17%, 21.5% | Anti-Depressent |
| Venlafaxine Pellets 33% | Anti-Depressent |
| Dexlansoprazole Pellets 20%, 23% | Proton Pump Inhibitor |
PRODUCTS UNDER DEVELOPMENT
| API’s | Category | R&D Sample availability | R&D Tech pack availability | Specifications |
|---|---|---|---|---|
| Canagliflozin Hemihydrate | Anti-Diabetic | Available | Available | In-House |
| Imipenem (Non-Sterile) | Carbapenems | Available | Available | In-House |
| Lacosamide | Anti-convulsants | Available | Available | EP/USP |
| Buspirone Hydrochloride | Anti-Anxiety Agent | Available | Oct 2024 | IP/EP/USP |
| Macitentan | Pulmonary Arterial Hypertension | Available | Sep 2024 | In-House |
| Riociguat | Pulmonary Arterial Hypertension | Available | Sep 2024 | EP/USP |
| Vericiguat | Pulmonary Arterial Hypertension | Oct 2024 | Jan 2025 | In-house |
| Ertugliflozin L-pyroglutamic acid | Anti-Diabetic | Available | Jan 2025 | In-House |
| Imipenem Cilastatin Sterile | ||||
| Ivacaftor | Cystic fibrosis | |||
| Mirogabalin | Neuropathic Pain |
PRODUCTS IN PIPELINE
| API | Therapeutic Category |
|---|---|
| Atogepant | Anti-migraine |
| Avatrombopag | Platelet enhancing drug |
| Bempedoic Acid | Anti-hypertensive/Cardiovascular |
| Brivaracetam | Anti-epileptic Neuromodulator |
| Finerenone | Cardiovascular Nephrology |
| Upadacitinib | Rheumatoid Arthritis |
| Vibegron | Overactive Bladder Renal Hypertension |
NOTE
- Products will not be offered for sale in countries where valid Patents are in force.
- It is the responsibility of the buyer to comply with the above.
For more information on API’s, send an e-mail to: api@kopran.com